Search

Congress Patient Benefit

The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent

EU approved Jardiance for type 2 diabetes in children

Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.

The liver and its vital connection to our overall health

How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction

BI Focuses COVID-19 Clinical Research on Alteplase

BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial

Boehringer Ingelheim partners with GNA Biosolutions

Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.

2020 European PRRS Research Award sponsorship

2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.

Second cancer immunotherapy partnership with 3T Bio

Accelerating new cancer medicines in partnership with CBmed

Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients

PRRS Research Award 2022

Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022

Joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial

Facts about the INPULSIS™ trials

Mastitis dairy cows prevent antibiotic resistance

The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.

Lameness horses collaboration Sleip app artificial intelligence

The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.

PRRS vaccine celebrates 25 years in Europe

Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe

Bringing Precision to Psychiatry

Dr. Hugh Marston discusses how precision psychiatry can enable people living with mental health conditions to thrive.

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status

emperor-reduced-heart-failure-toplineresults

Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction

FDA Grants Breakthrough Status to Schizophrenia Treatment

Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers